Mirati Therapeutics Inc (NASDAQ:MRTX) Director Aaron I. Davis sold 50,000 shares of the stock in a transaction on Tuesday, January 8th. The shares were sold at an average price of $47.68, for a total transaction of $2,384,000.00. Following the completion of the sale, the director now directly owns 70,409 shares of the company’s stock, valued at $3,357,101.12. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Shares of MRTX stock opened at $60.79 on Friday. Mirati Therapeutics Inc has a 52-week low of $21.50 and a 52-week high of $65.35. The firm has a market capitalization of $1.46 billion, a PE ratio of -21.87 and a beta of 1.49.
Mirati Therapeutics (NASDAQ:MRTX) last announced its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.02. Sell-side analysts forecast that Mirati Therapeutics Inc will post -3.12 earnings per share for the current year.
A number of analysts have weighed in on the stock. BidaskClub downgraded shares of Mirati Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, September 28th. HC Wainwright reissued a “buy” rating and issued a $65.00 price target on shares of Mirati Therapeutics in a report on Monday, November 12th. Zacks Investment Research raised shares of Mirati Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, October 4th. Oppenheimer set a $62.00 price target on shares of Mirati Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 30th. Finally, reissued a “buy” rating and issued a $57.00 price target (down from $62.00) on shares of Mirati Therapeutics in a report on Tuesday, November 6th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. Mirati Therapeutics currently has a consensus rating of “Buy” and an average price target of $54.89.
WARNING: This piece was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://dakotafinancialnews.com/2019/01/11/mirati-therapeutics-inc-mrtx-director-aaron-i-davis-sells-50000-shares.html.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC.
Further Reading: How interest rates affect municipal bond prices
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.